Memory CD8 T cell immunity to respiratory viral infections
记忆 CD8 T 细胞对呼吸道病毒感染的免疫
基本信息
- 批准号:8699313
- 负责人:
- 金额:$ 35.49万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2013
- 资助国家:美国
- 起止时间:2013-08-01 至 2015-07-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAntibodiesAreaBiologyCD8B1 geneCellsCellular biologyCharacteristicsCoronavirusDataDevelopmentDiseaseEthicsFlushieldGenerationsGoalsHealthHumanImmunityInfectionInfluenza A virusKnowledgeLungLung diseasesMediatingMemoryModelingMorbidity - disease rateMurine hepatitis virusMusNosePhysiologyPlayPrimatesPrincipal InvestigatorProteinsReagentRegulatory T-LymphocyteResistanceRespiratory Tract DiseasesRespiratory Tract InfectionsRespiratory syncytial virusRoleSendai virusSymptomsSystemT cell responseT memory cellT-LymphocyteTranscendVaccinatedVaccinesViralVirusVirus DiseasesWorkbaseexperienceimmunopathologyimprovedinfancyinfluenza virus vaccineinfluenzavirusinsightmortalityneutralizing antibodynovelpathogenprogramsrespiratoryrespiratory infection virusrespiratory virusseasonal influenzatranslational approachvaccine deliveryvaccine development
项目摘要
DESCRIPTION (provided by applicant): The goal of this project is to address basic knowledge gaps relating to memory CD8 T cell mediated protection against respiratory virus infections. Our goal is to provide mechanistic experimental insight into the cellular basis for immunity to respiratory virus infection and thus, we will employ the sophisticated reagents and range of respiratory virus infection models available in mice. In this way, we expect to identify both common and pathogen-specific aspects of memory CD8 T cell immunity against viruses that cause respiratory infection. These studies cannot be carried out in humans for ethical reasons; however, we anticipate that our mechanistic data will provide important information to inform new generation vaccine development. Additionally, to date, efforts devoted towards developing translatable efficient vaccine delivery systems to induce memory CD8 T cell responses against respiratory virus infections remain at their infancy. The long-term goal of this proposal is to utilize our expertise in memory CD8 T cell biology to identify characteristics that permit optimal protective immunity against a spectrum of respiratory viruses. In addition, we will build on novel preliminary data to evaluate translatable approaches (such as the nasal influenza vaccine, Flumist") to prime CD8 T cell responses that can be boosted to provide high level, subtype transcending immunity to respiratory infection. In this proposal, we will build on our exciting preliminary data to address these long-term goals through the following specific aims: Aim 1. Determine the magnitude and cellular interactions required for memory CD8 T cell immunity against a spectrum of respiratory viral infections including IAV, RSV and MHV- 1. Aim 2. Define the optimal characteristics for memory CD8 T cell immunity against a spectrum of respiratory viral infections. Aim 3. Develop novel translational approaches to generate memory CD8 T cells that provide optimal protection against respiratory viral infections.
描述(由申请人提供):这个项目的目标是解决与记忆CD8 T细胞介导的预防呼吸道病毒感染相关的基本知识空白。我们的目标是提供对呼吸道病毒感染免疫的细胞学基础的机械性实验洞察,因此,我们将使用先进的试剂和一系列在小鼠身上可用的呼吸道病毒感染模型。通过这种方式,我们希望识别记忆CD8 T细胞免疫的共同和病原体特异性方面,以对抗导致呼吸道感染的病毒。由于伦理原因,这些研究不能在人类身上进行;然而,我们预计我们的机械数据将提供重要信息,为新一代疫苗的开发提供信息。此外,迄今为止,致力于开发可翻译的高效疫苗递送系统以诱导针对呼吸道病毒感染的记忆CD8 T细胞反应的努力仍处于初级阶段。这项建议的长期目标是利用我们在记忆CD8 T细胞生物学方面的专业知识来确定允许对一系列呼吸道病毒产生最佳保护性免疫的特征。此外,我们将基于新的初步数据来评估可翻译的方法(如鼻流感疫苗,Flumist“),以启动CD8 T细胞反应,这些反应可以增强,以提供对呼吸道感染的高水平、亚型以上的免疫。在这项提案中,我们将以我们令人兴奋的初步数据为基础,通过以下具体目标来解决这些长期目标:目标1.确定针对包括IAV、RSV和MHV-1在内的一系列呼吸道病毒感染的记忆CD8 T细胞免疫所需的大小和细胞相互作用。目标2.确定针对一系列呼吸道病毒感染的记忆CD8 T细胞免疫的最佳特征。目的3.开发新的翻译方法来产生记忆CD8 T细胞,以提供对呼吸道病毒感染的最佳保护。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
John T Harty其他文献
John T Harty的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('John T Harty', 18)}}的其他基金
Regulating Pathogen-induced Protective and Pathogenic CD8 T cells in the CNS
调节中枢神经系统中病原体诱导的保护性和致病性 CD8 T 细胞
- 批准号:
10722304 - 财政年份:2023
- 资助金额:
$ 35.49万 - 项目类别:
T cell Inhibitory receptor blockade in chronic blood-stage malaria
慢性血期疟疾中的 T 细胞抑制性受体阻断
- 批准号:
8369810 - 财政年份:2012
- 资助金额:
$ 35.49万 - 项目类别:
T cell Inhibitory receptor blockade in chronic blood-stage malaria
慢性血期疟疾中的 T 细胞抑制性受体阻断
- 批准号:
8830912 - 财政年份:2012
- 资助金额:
$ 35.49万 - 项目类别:
T cell Inhibitory receptor blockade in chronic blood-stage malaria
慢性血期疟疾中的 T 细胞抑制性受体阻断
- 批准号:
8639463 - 财政年份:2012
- 资助金额:
$ 35.49万 - 项目类别:
Understanding immune regulation in blood-stage malaria
了解血期疟疾的免疫调节
- 批准号:
10192639 - 财政年份:2012
- 资助金额:
$ 35.49万 - 项目类别:
T cell Inhibitory receptor blockade in chronic blood-stage malaria
慢性血期疟疾中的 T 细胞抑制性受体阻断
- 批准号:
8462904 - 财政年份:2012
- 资助金额:
$ 35.49万 - 项目类别:
T cell Inhibitory receptor blockade in chronic blood-stage malaria
慢性血期疟疾中的 T 细胞抑制性受体阻断
- 批准号:
9054060 - 财政年份:2012
- 资助金额:
$ 35.49万 - 项目类别:
T cell immunity to Plasmodium sporozoite immunization
T细胞对疟原虫子孢子免疫的免疫
- 批准号:
8585021 - 财政年份:2011
- 资助金额:
$ 35.49万 - 项目类别:
相似海外基金
University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
- 批准号:
10073243 - 财政年份:2024
- 资助金额:
$ 35.49万 - 项目类别:
Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
- 批准号:
10752129 - 财政年份:2024
- 资助金额:
$ 35.49万 - 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
- 批准号:
2339201 - 财政年份:2024
- 资助金额:
$ 35.49万 - 项目类别:
Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
- 批准号:
MR/Y008693/1 - 财政年份:2024
- 资助金额:
$ 35.49万 - 项目类别:
Research Grant
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
- 批准号:
23K14783 - 财政年份:2023
- 资助金额:
$ 35.49万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
- 批准号:
23KJ0394 - 财政年份:2023
- 资助金额:
$ 35.49万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
- 批准号:
10076445 - 财政年份:2023
- 资助金额:
$ 35.49万 - 项目类别:
Grant for R&D
PLA2G2D Antibodies for Cancer Immunotherapy
用于癌症免疫治疗的 PLA2G2D 抗体
- 批准号:
10699504 - 财政年份:2023
- 资助金额:
$ 35.49万 - 项目类别:
Genetic adjuvants to elicit neutralizing antibodies against HIV
基因佐剂可引发抗艾滋病毒中和抗体
- 批准号:
10491642 - 财政年份:2023
- 资助金额:
$ 35.49万 - 项目类别:
Novel Immunogens to Elicit Broadly Cross-reactive Antibodies That Target the Hemagglutinin Head Trimer Interface
新型免疫原可引发针对血凝素头三聚体界面的广泛交叉反应抗体
- 批准号:
10782567 - 财政年份:2023
- 资助金额:
$ 35.49万 - 项目类别: